{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:49:46Z","timestamp":1764251386510},"reference-count":50,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.3892\/ijo.2015.3170","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T12:48:50Z","timestamp":1442407730000},"page":"1735-1748","source":"Crossref","is-referenced-by-count":17,"title":["Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-\u03b1 fusion protein: Direct cytotoxicity and synergy with chemotherapy"],"prefix":"10.3892","volume":"47","author":[{"given":"GABRIEL G.","family":"VEGA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LUZ ARELI","family":"FRANCO-CEA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SARA","family":"HUERTA-YEPEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00c9CTOR","family":"MAYANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHERIE L.","family":"MORRISON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BENJAMIN","family":"BONAVIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARIO I.","family":"VEGA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,9,16]]},"reference":[{"key":"key20180107190858_b1-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107190858_b2-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"key20180107190858_b3-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"key20180107190858_b4-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"key20180107190858_b5-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20180107190858_b6-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1080\/10428190802357071","article-title":"The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs","volume":"49","author":"Vega","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180107190858_b7-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2010.157","article-title":"HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells","volume":"24","author":"Shimizu","year":"2010","journal-title":"Leukemia"},{"key":"key20180107190858_b8-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11899-012-0133-2","article-title":"Biological therapy doublets: Pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma","volume":"7","author":"Kimby","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"key20180107190858_b9-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","article-title":"T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab","volume":"17","author":"Wahlin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107190858_b10-ijo-47-05-1735","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and inter-feron-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180107190858_b11-ijo-47-05-1735","first-page":"951","article-title":"GISL: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"86","author":"Sacchi","year":"2001","journal-title":"Haematologica"},{"key":"key20180107190858_b12-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","article-title":"Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group","volume":"49","author":"Kimby","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180107190858_b13-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"key20180107190858_b14-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/jir.2006.26.421","article-title":"IFN-alpha sensitizes daudi B lymphoma cells to anti-IgM induced loss of mitochondrial membrane potential through activation of c-Jun NH(2)-terminal kinase","volume":"26","author":"Hayashida","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"key20180107190858_b15-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","article-title":"Cytokine therapeutics: Lessons from interferon alpha","volume":"91","author":"Gutterman","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"key20180107190858_b16-ijo-47-05-1735","first-page":"89","article-title":"Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986","volume":"14","author":"Spielberger","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"key20180107190858_b17-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2121-13-7","article-title":"PKC-\u03b4 mediates interferon-\u03b1-induced apoptosis through c-Jun NH(2)-terminal kinase activation","volume":"13","author":"Yanase","year":"2012","journal-title":"BMC Cell Biol"},{"key":"key20180107190858_b18-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107190858_b19-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","article-title":"Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma","volume":"115","author":"Xuan","year":"2010","journal-title":"Blood"},{"key":"key20180107190858_b20-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107190858_b21-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","article-title":"Rituximab-mediated cell signaling and chemo\/immunosensitization of drug-resistant B-NHL is independent of its Fc functions","volume":"15","author":"Vega","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107190858_b22-ijo-47-05-1735","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107190858_b23-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"key20180107190858_b24-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1038\/sj.onc.1207336","article-title":"Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance","volume":"23","author":"Vega","year":"2004","journal-title":"Oncogene"},{"key":"key20180107190858_b25-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"key20180107190858_b26-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/sj.onc.1203524","article-title":"Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes","volume":"19","author":"Kotenko","year":"2000","journal-title":"Oncogene"},{"key":"key20180107190858_b27-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"key20180107190858_b28-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cyto.2011.12.001","article-title":"Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: Differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma","volume":"57","author":"Salamon","year":"2012","journal-title":"Cytokine"},{"key":"key20180107190858_b29-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2009-06-227017","article-title":"Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells","volume":"115","author":"Basso","year":"2010","journal-title":"Blood"},{"key":"key20180107190858_b30-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1101\/gad.12.13.1953","article-title":"Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor","volume":"12","author":"Niu","year":"1998","journal-title":"Genes Dev"},{"key":"key20180107190858_b31-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/ni1508","article-title":"Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells","volume":"8","author":"Phan","year":"2007","journal-title":"Nat Immunol"},{"key":"key20180107190858_b32-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in normal and transformed germinal center B cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol Rev"},{"key":"key20180107190858_b33-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"key20180107190858_b34-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J Clin Invest"},{"key":"key20180107190858_b35-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"e67900","DOI":"10.1371\/journal.pone.0067900","article-title":"CD20 antibody primes B lymphocytes for type I interferon production","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"key20180107190858_b36-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.4049\/jimmunol.161.7.3242","article-title":"Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment","volume":"161","author":"Polyak","year":"1998","journal-title":"J Immunol"},{"key":"key20180107190858_b37-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbrc.2007.02.053","article-title":"Dynamic interplay between the neutral glycosphingolipid CD77\/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells","volume":"355","author":"Jarvis","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107190858_b38-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.leukres.2004.02.008","article-title":"Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces","volume":"28","author":"Holder","year":"2004","journal-title":"Leuk Res"},{"key":"key20180107190858_b39-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<97::AID-JCP11>3.0.CO;2-Y","article-title":"Functional significance of globotriaosyl ceramide in interferon-alpha(2)\/type 1 interferon receptor-mediated antiviral activity","volume":"182","author":"Khine","year":"2000","journal-title":"J Cell Physiol"},{"key":"key20180107190858_b40-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1023\/A:1007145420116","article-title":"Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells","volume":"16","author":"Maloney","year":"1999","journal-title":"Glycoconj J"},{"key":"key20180107190858_b41-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2009-06-228890","article-title":"CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas","volume":"114","author":"Rossi","year":"2009","journal-title":"Blood"},{"key":"key20180107190858_b42-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1158\/0008-5472.CAN-10-2126","article-title":"A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells","volume":"70","author":"Rossi","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107190858_b43-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1021640817208","article-title":"Regulation of cell apoptosis by protein kinase c delta","volume":"8","author":"Brodie","year":"2003","journal-title":"Apoptosis"},{"key":"key20180107190858_b44-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1096\/fj.03-0979rev","article-title":"The enigmatic protein kinase Cdelta: Complex roles in cell proliferation and survival","volume":"18","author":"Jackson","year":"2004","journal-title":"FASEB J"},{"key":"key20180107190858_b45-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1042\/BST0351001","article-title":"Protein kinase Cdelta and apoptosis","volume":"35","author":"Reyland","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"key20180107190858_b46-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.2003.tb06040.x","article-title":"B cell immunity regulated by the protein kinase C family","volume":"987","author":"Saijo","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"key20180107190858_b47-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1089\/107999000750053799","article-title":"Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells","volume":"20","author":"Yanase","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"key20180107190858_b48-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yexcr.2005.06.021","article-title":"Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells","volume":"310","author":"Yanase","year":"2005","journal-title":"Exp Cell Res"},{"key":"key20180107190858_b49-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.exphem.2005.01.014","article-title":"Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells","volume":"33","author":"Kaur","year":"2005","journal-title":"Exp Hematol"},{"key":"key20180107190858_b50-ijo-47-05-1735","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.278.5343.1630","article-title":"Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases","volume":"278","author":"Kumar","year":"1997","journal-title":"Science"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3170\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:51:27Z","timestamp":1691992287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,16]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,9,16]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.3892\/ijo.2015.3170"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3170","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,16]]}}}